GBG Forschungs GmbH (German Breast Group)

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study (2019) Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, et al. Journal article Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, et al. Journal article Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) (2019) Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Luebbe K, et al. Journal article Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (2019) Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, et al. Journal article Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) Witzel I, Loibl S, Wirtz R, Fasching P, Denkert C, Weber K, Lück HJ, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, et al. Journal article Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant geparsepto trial (2019) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Journal article Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019) Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P, et al. Journal article